Intervention not reported
Duration of mechanical ventilation (days) · Preterm neonates with respiratory distress
1 finding from 1 review
Intervention not reported
Duration of supplemental oxygen (days) · Preterm neonates with respiratory distress
1 finding from 1 review
Intervention not reported
Hyperglycaemia · Preterm neonates with respiratory distress
The intervention probably leads to lower hyperglycaemia (moderate certainty).
1 finding from 1 review
Intervention not reported
Patent ductus arteriosus · Preterm neonates with respiratory distress
The intervention probably leads to higher patent ductus arteriosus (moderate certainty).
1 finding from 1 review
Intervention not reported
BPD at 36 weeks' postmenstrual age · Preterm neonates with respiratory distress
The intervention showed no clear difference in BPD at 36 weeks' postmenstrual age (moderate certainty).
1 finding from 1 review
Intervention not reported
Change from baseline in mean asthma symptom score Greater the reduction, better the outcome Duration of trials: 12 to 13 weeks · adults and adolescents with persistent asthma
1 finding from 1 review
Intervention not reported
Overall adverse effects Duration of trials: 8 to 16 weeks · adults and adolescents with persistent asthma
The intervention showed no clear difference in overall adverse effects Duration of trials: 8 to 16 weeks (low certainty).
1 finding from 1 review
Intervention not reported
Death Duration of trials: 12 to 13 weeks · adults and adolescents with persistent asthma
1 finding from 1 review
Intervention not reported
% change from baseline ICS dose Duration of trials: 12 to 24 weeks More reduction is better · adults and adolescents with persistent asthma
1 finding from 1 review
Intervention not reported
Change from baseline in morning PEFR (L/min) Duration of trials: 12 to 24 weeks · adults and adolescents with persistent asthma
1 finding from 1 review
Intervention not reported
Overall adverse effects Duration of trials: 8 to 24 weeks · adults and adolescents with persistent asthma
The intervention showed no clear difference in overall adverse effects Duration of trials: 8 to 24 weeks (moderate certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events Duration of trials: 12 to 20 weeks · adults and adolescents with persistent asthma
The intervention probably leads to higher serious adverse events Duration of trials: 12 to 20 weeks (moderate certainty).
1 finding from 1 review
Intervention not reported
Death Duration of trials: 8 to 24 weeks · adults and adolescents with persistent asthma
The intervention showed no clear difference in death Duration of trials: 8 to 24 weeks (low certainty).
1 finding from 1 review
Intervention not reported
Change from baseline in morning PEFR (L/min) Duration of trials: 6 to 16 weeks · adults and adolescents with persistent asthma
1 finding from 1 review
Intervention not reported
Change from baseline FEV1 (L) Duration of trials: 6 to 16 weeks · adults and adolescents with persistent asthma
1 finding from 1 review
Intervention not reported
Change from baseline in mean asthma symptom score (daytime) Greater the reduction, better the outcome Duration of trials: 6 to 16 weeks · adults and adolescents with persistent asthma
1 finding from 1 review
Intervention not reported
Overall adverse effects Duration of trials: 6 to 16 weeks · adults and adolescents with persistent asthma
The intervention showed no clear difference in overall adverse effects Duration of trials: 6 to 16 weeks (moderate certainty).
1 finding from 1 review
Intervention not reported
Death Duration of trials: 6 to 16 weeks · adults and adolescents with persistent asthma
The intervention showed no clear difference in death Duration of trials: 6 to 16 weeks (low certainty).
1 finding from 1 review
Intervention not reported
Change from baseline in morning PEFR (L/min) Duration of trials: 8 to 13 weeks · adults and adolescents with persistent asthma
1 finding from 1 review
Intervention not reported
Change from baseline FEV1 (L) Duration of trials: 8 to 13 weeks · adults and adolescents with persistent asthma
1 finding from 1 review